Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Regulation of Hematopoietic Stem Cells01:01

Regulation of Hematopoietic Stem Cells

4.2K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.2K
Hematopoiesis01:21

Hematopoiesis

9.5K
The process of blood cell formation is called hematopoiesis. Hematopoiesis starts early during development, on the seventh day of embryogenesis. This phase of hematopoiesis is called the primitive wave, wherein the extraembryonic yolk sac allows the production of erythroid cells and endothelial cells from a common precursor called hemangioblast. The erythroid cells provide oxygen to support the growth of the rapidly dividing embryo. Hemangioblasts later develop into hematopoietic stem cells or...
9.5K
Multipotency of Hematopoietic Stem Cells01:19

Multipotency of Hematopoietic Stem Cells

4.0K
The hematopoietic stem cells or HSCs are multipotent, meaning they can differentiate and give rise to all blood and immune cells. HSCs are maintained in the quiescent stage until an external stimulus initiates their differentiation. The multipotent HSCs exist as two heterogeneous populations, long-term repopulating cells (LTRC) and short-term repopulating cells (STRC). The two HSC populations have different surface markers or receptors and are classified based on quiescence and long-term...
4.0K
Role of Hematopoietic Growth Factors01:28

Role of Hematopoietic Growth Factors

4.2K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
4.2K
Overview of Hematopoiesis01:20

Overview of Hematopoiesis

10.8K
Hematopoiesis, or blood cell production, is a vital biological process that begins early in embryonic development and continues throughout life. This process generates the various types of cells found in blood, including red blood cells, white blood cells, and platelets from hematopoietic stem cells (HSCs).
Developmental Phases of Hematopoiesis
Initially, HSCs are formed in the embryonic yolk sac, a critical site for early blood cell production. These stem cells subsequently migrate to other...
10.8K
Lineage Commitment01:21

Lineage Commitment

4.5K
Commitment is the  process whereby stem cells:
4.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short ramp-up glofitamab halves mortality risk after anti-CD19 CAR T-cell therapy failure in patients with diffuse large B-cell lymphoma: final results of the LYSA BiCAR phase 2 trial with a pre-specified external control arm.

Journal of hematology & oncology·2026
Same author

Prediction of bone marrow fibrosis from complete blood count in myeloproliferative neoplasms (FIBOM-AI): a multicentre machine learning model development and validation study.

The Lancet. Haematology·2026
Same author

Nivolumab with or without vinblastine for first-line treatment of elderly patients with Hodgkin lymphoma and coexisting medical conditions: the Niviniho phase II Lysa study.

Haematologica·2026
Same author

TLR7 induces autophagy in non-small cell lung cancer tumor cells and influences anti-tumors responses in patients.

Translational lung cancer research·2026
Same author

Prolonged survival with glofitamab in non-diffuse large B-cell lymphoma after CAR T-cell therapy relapse.

Haematologica·2026
Same author

Clonal Lymphocyte Expansions and JAK-STAT Pathway Mutations Define a Pathogenic Continuum Driving Resistance to Gluten-Free Diet in Celiac Disease.

Gastroenterology·2026
Same journal

[Case no. 2. Pseudotumoral pulmonary IgG4 disease].

Annales de pathologie·2026
Same journal

[Diffuse large B-cell lymphoma-NOS , high-grade B-cell lymphomas and Burkitt lymphoma: Updates].

Annales de pathologie·2026
Same journal

[Ironing out the diagnosis].

Annales de pathologie·2026
Same journal

[Ecological transformation and quality of surgical pathological analysis: Not such an insoluble equation].

Annales de pathologie·2026
Same journal

[Cerebrospinal fluid in the context of headaches with decreased visual acuity].

Annales de pathologie·2026
Same journal

[Facial granulomatous lesion in a traveler].

Annales de pathologie·2026
See all related articles

Related Experiment Video

Updated: Mar 8, 2026

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.5K

[Immune-checkpoint and hemopathies].

Barbara Burroni1, Chloé Broudin1, Diane Damotte2

  • 1Service de pathologie, hôpital Cochin, AP-HP , 75014 Paris, France.

Annales De Pathologie
|February 6, 2017
PubMed
Summary
This summary is machine-generated.

Immune-checkpoint inhibitors show promise for treating refractory lymphomas, offering new hope for patients with poor prognoses. These therapies, targeting CTLA4, PD-1, and PD-L1, improve survival rates in aggressive lymphoma cases.

Keywords:
Cellules immunitairesHemopathiesHémopathiesImmune cellsPD-1PD-L1

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

16.0K

Related Experiment Videos

Last Updated: Mar 8, 2026

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research
08:17

A Human Peripheral Blood Mononuclear Cell PBMC Engrafted Humanized Xenograft Model for Translational Immuno-oncology I-O Research

Published on: August 15, 2019

15.5K
Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells
09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

1.8K
Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness
08:53

Competitive Transplants to Evaluate Hematopoietic Stem Cell Fitness

Published on: August 31, 2016

16.0K

Area of Science:

  • Oncology
  • Immunology
  • Hematology

Background:

  • Lymphomas, cancers of the immune system, often respond to conventional treatments.
  • Relapsed or refractory lymphomas present a significant clinical challenge with poor prognoses.
  • Novel immunotherapies are crucial for managing aggressive and treatment-resistant lymphoma.

Purpose of the Study:

  • To evaluate the efficacy of immune-checkpoint inhibitors in treating various lymphoma subtypes.
  • To explore the role of PD-L1 expression in lymphoma diagnosis and predicting treatment response.
  • To understand the unique mechanisms of immunotherapies in lymphomas compared to solid tumors.

Main Methods:

  • Review of clinical data on immune-checkpoint inhibitors targeting CTLA4, PD-1, and PD-L1 in lymphoma patients.
  • Analysis of PD-L1 expression patterns in different lymphoma subtypes.
  • Comparison of lymphoma and solid tumor responses to immunotherapies.

Main Results:

  • Immune-checkpoint inhibitors demonstrate significant efficacy, leading to prolonged survival, even post-bone marrow allograft for aggressive lymphomas.
  • PD-L1 expression in lymphomas is often linked to molecular alterations like gene amplification or mutation.
  • PD-L1 protein expression frequency and distribution vary by lymphoma subtype, potentially aiding diagnosis and response prediction.

Conclusions:

  • Immune-checkpoint inhibitors are potent therapies for lymphomas, especially refractory cases.
  • Lymphoma cells' immune origin allows immunotherapies to target both tumor and immune cells.
  • PD-L1 expression serves as a potential biomarker for diagnosis and therapeutic response in lymphoma.